Hallmark analysis of the 359 genes whose expression levels in spinal cords were only corrected by the combinatorial treatment revealed enrichment of immune‐related pathways, such as TNF‐α signalling, interferon response, and complement activation, overall suggesting that therapeutic targeting of neuroinflammation is key to achieving optimal and long‐lasting effects in SMA. The gene discussed is TNF; the disease is proximal spinal muscular atrophy.